Prostate-Specific Antigen (PSA) Bounces Following Stereotactic Body Radiotherapy for Prostate Cancer: Importance of PSA Test Frequency
Urology Journal,
Vol. 21 No. 06 (2024),
27 November 2024
,
Page 384-389
https://doi.org/10.22037/uj.v21i.8119
Abstract
Purpose: Prostate-specific antigen (PSA) bounce is a common phenomenon that can be observed in patients of
prostate cancer treated by radiotherapy. However, the clinical, pathological, or dosimetric predictors and clinical
significance of PSA bounce in stereotactic body radiotherapy (SBRT) patients is still unknown.
Methods: Between August 2006 to December 2015, 74 prostate cancer patients were treated by SBRT with Cyberknife at two medical centers. The prescription dose was 35-37.5 Gy in 5 fractions. Follow-up PSA tests were
more frequently performed in one hospital than the other (median 4 vs. 10 times for initial one year). PSA bounce
was defined as a rise of 0.2 ng/mL followed by a decline to or below the previous nadir.
Results: A total of 74 patients, PSA bounce was observed in 41 patients (55.4%). On univariate analysis, the treated
medical center (p = 0.02), PSA follow-up frequency (p = 0.01), patient age (p < 0.01), and total prescription
dose (p = 0.03) were significant clinical factors in predicting the incidence of PSA bounce, while in multivariable
analysis only the PSA follow-up frequency, and patient age remains significant.
Conclusion: PSA bounce was seen in a significant proportion of patients after Cyberknife SBRT. The PSA follow-
up test frequency, and patient age were significant factors that were correlated with the incidence of PSA
bounces in this study.
- , prostate cancer
- Prostate specific antigen
- prostate specific antigen fluctuation
- radiotherapy
How to Cite
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-49.
Hong S, Won YJ, Lee JJ, et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018. Cancer Res Treat. 2021;53:301-15.
Basiri A, Eshrati B, Zarehoroki A, et al. Incidence, Gleason Score and Ethnicity Pattern of Prostate Cancer in the Multi-ethnicity Country of Iran During 2008-2010. Urol J. 2020;17:602-6.
Rosser CJ, Kuban DA, Levy LB, et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol. 2002;168:2001-5.
Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21:383-91.
Amiri M, Asadi Samani L, Kashi AH, Khadem N, Ziaee SAM, Mowla SJ. New Molecular Markers for Prostate Cancer Diagnosis. Urol J. 2024;21:1-13.
Fitzpatrick JM, Banu E, Oudard S. Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int. 2009;103:578-87.
Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol. 2000;163:1085-9.
Stock RG, Stone NN, Cesaretti JA. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys. 2003;56:448-53.
Ciezki JP, Reddy CA, Garcia J, et al. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys. 2006;64:512-7.
Horwitz EM, Levy LB, Thames HD, et al. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer. 2006;107:1496-502.
Vu CC, Haas JA, Katz AE, Witten MR. Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer. Front Oncol. 2014;4:8.
Kole TP, Chen LN, Obayomi-Davies O, et al. Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer. Acta Oncol. 2015;54:832-8.
Darwis NDM, Oike T, Kubo N, Gondhowiardjo SA, Ohno T. Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis. Cancers (Basel). 2020;12.
Jiang NY, Dang AT, Yuan Y, et al. Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019;105:628-36.
Roach M, 3rd, Hanks G, Thames H, Jr., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965-74.
Kishan AU. PSA bounce, prognosis, and clues to the radiation response. Prostate Cancer Prostatic Dis. 2021;24:937-8.
Caloglu M, Ciezki J. Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon. Urology. 2009;74:1183-90.
Urabe F, Kimura S, Tashiro K, et al. Prognostic value of PSA bounce in prostate cancer following definitive radiation therapy: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021;24:976-85.
Sölétormos G, Semjonow A, Sibley PE, et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem. 2005;51:1342-51.
Hamidi N, Atmaca AF, Canda AE, Keske M, Ardıçoğlu A. Does extent of prostate-specific antigen fluctuation can predict Gleason score upgrading in low-risk prostate cancer patients? Turk J Urol. 2019;45:S42-s8.
Park YH, Choi IY, Yoon SC, et al. Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer. Prostate Int. 2015;3:6-9.
Herkommer K, Meissner VH, Hollerer M, et al. Effect of sexual behavior on prostate-specific antigen levels in middle-aged men screened for prostate cancer: results from the probase trial. J Urol 2020;203:e1143
Matsushima M, Kikuchi E, Matsumoto K, et al. Erectile function status is highly associated with prostate-specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy. Int J Urol. 2016;23:247-52.
Greenland S, Mansournia MA, Altman DG. Sparse data bias: a problem hiding in plain sight. BMJ. 2016;352:i1981.
- Abstract Viewed: 601 times
- 8119/pdf Downloaded: 250 times